This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, J. Articles by Reynolds, R. K. Search for Related Content PubMed PubMed Citation Articles by Lin, J. Articles by Reynolds, R. K.

A Modified p53 Overcomes mdm2-mediated Oncogenic Transformation: A Potential Cancer Therapeutic Agent¹

Department of Obstetrics and Gynecology [J. L., X. J., C. P., R. K. R.] and Department of Surgery [V. K. S., G. J.], University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109

The antiproliferative activities of wild-type (wt) p53 are inhibited by mdm2 (murine double minute2) oncogene product. We tested growth suppression activity of p53 14/19, an engineered p53 variant, which does not bind mdm2 and is completely resistant to the inhibition by mdm2. p53 14/19, unlike wt p53, suppressed the growth of cancer cells that contain amplified mdm2 oncogene efficiently by direct DNA transfection or adenovirus-mediated gene transfer. In addition, p53 14/19 also inhibited the growth of several different cancer cell lines expressing low levels of mdm2 oncogene product as efficiently as wt p53. We further examined the antioncogenic potencies of p53 14/19 in the rat embryo fibroblast cotransformation assay. Addition of wt p53 failed to cause any significant decrease in ras plus mdm2 foci counts. In contrast, cotransfection of p53 14/19 with ras and mdm2 significantly reduced foci number. In similar experiments, cotransfection of wt p53 or 14/19 p53 resulted in significant inhibition of oncogenic transformation in rat embryo fibroblast mediated by an activated ras plus c-myc, adenovirus E1A, or human papillomavirus E7 oncogenes. Therefore, these results suggest that p53 14/19 modified tumor suppressor gene may be a promising therapeutic agent for human cancers that express abnormally high levels of mdm2 oncogene product.

This article has been cited by other articles:

				Y. C. Shin, H. Nakamura, X. Liang, P. Feng, H. Chang, T. F. Kowalik, and J. U. Jung Inhibition of the ATM/p53 Signal Transduction Pathway by Kaposi's Sarcoma-Associated Herpesvirus Interferon Regulatory Factor 1 J. Virol., March 1, 2006; 80(5): 2257 - 2266. [Abstract] [Full Text] [PDF]

				V. W. van Beusechem, P. B. van den Doel, and W. R. Gerritsen Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2 Mol. Cancer Ther., June 1, 2005; 4(6): 1013 - 1018. [Abstract] [Full Text] [PDF]

				C. Li, L. Chen, and J. Chen DNA Damage Induces MDMX Nuclear Translocation by p53-Dependent and -Independent Mechanisms Mol. Cell. Biol., November 1, 2002; 22(21): 7562 - 7571. [Abstract] [Full Text] [PDF]

				W. Lu, J. Lin, and J. Chen Expression of p14ARF Overcomes Tumor Resistance to p53 Cancer Res., March 1, 2002; 62(5): 1305 - 1310. [Abstract] [Full Text] [PDF]

				S. Heessen, A. Leonchiks, N. Issaeva, A. Sharipo, G. Selivanova, M. G. Masucci, and N. P. Dantuma Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis PNAS, January 17, 2002; (2002) 22306499. [Abstract] [Full Text] [PDF]

				J. Lin, X. Jin, K. Rothman, H.-J. Lin, H. Tang, and W. Burke Modulation of Signal Transducer and Activator of Transcription 3 Activities by p53 Tumor Suppressor in Breast Cancer Cells Cancer Res., January 1, 2002; 62(2): 376 - 380. [Abstract] [Full Text] [PDF]

				S. Heessen, A. Leonchiks, N. Issaeva, A. Sharipo, G. Selivanova, M. G. Masucci, and N. P. Dantuma Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis PNAS, February 5, 2002; 99(3): 1532 - 1537. [Abstract] [Full Text] [PDF]